☆ 4.6 Review

Optimizing Foundational Therapies in Patients With HFrEF How Do We Translate These Findings Into Clinical Care?

JACC-BASIC TO TRANSLATIONAL SCIENCE (2022)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes -Systematic review and meta-analysis of randomized placebo-controlled trials

Husam M. Salah et al.

Summary: In patients with cardiometabolic and kidney disease, SGLT2i improved cardiovascular and kidney outcomes, regardless of T2DM, HF, and/or CKD status. The most significant risk reduction was seen in hospitalization for HF and progression of kidney disease, while the effects on mortality, MI, and stroke varied.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction

Robert J. H. Miller et al.

Summary: The rapid initiation and titration of four Foundational Therapies can lead to significant reduction in morbidity and mortality for most HFrEF patients. Additional benefits may be observed with the addition of personalized therapies in specific patient subgroups.

CANADIAN JOURNAL OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine

John J. V. McMurray et al.

CIRCULATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction A Report of the American College of Cardiology Solution Set Oversight Committee

Thomas M. Maddox et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Disease and Stroke Statistics-2021 Update A Report From the American Heart Association

Salim S. Virani et al.

Summary: The American Heart Association, in partnership with the National Institutes of Health, publishes annual statistics on heart disease, stroke, and cardiovascular risk factors, including the impact of health behaviors and factors on cardiovascular health. The Statistical Update covers a range of clinical heart and circulatory conditions, providing data on quality of care, procedures, and economic costs. It serves as a critical resource for various stakeholders seeking the best available data on these factors and conditions.

CIRCULATION (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction

Milton Packer et al.

Summary: The foundational therapy for heart failure includes four types of drugs, and a rapid sequencing strategy is proposed to start all treatments within 2-4 weeks for improved efficacy in reducing morbidity and mortality.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Expediting the Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure-There Is No Time for Delay

Gregg C. Fonarow et al.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

David D. Berg et al.

Summary: The study showed that treatment with dapagliflozin can rapidly reduce the risk of cardiovascular death or worsening heart failure, with patients who had recent HF hospitalization experiencing greater relative and absolute risk reductions with dapagliflozin.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice The Get With the Guidelines-Heart Failure (GWTG-HF) Registry

Muthiah Vaduganathan et al.

Summary: This study suggests that 4 of 5 patients with heart failure with reduced ejection fraction (HFrEF) in the US, regardless of type 2 diabetes, would be candidates for initiation of dapagliflozin, indicating its broad generalizability in US clinical practice.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction

Michael McDonald et al.

Summary: This article provides comprehensive recommendations and practical tips for pharmacologic management of patients with heart failure with reduced ejection fraction (HFrEF), focusing on novel pharmacologic therapies. A new standard of pharmacologic care for HFrEF is defined, emphasizing the integration of prioritized pharmacologic with nonpharmacologic and invasive therapies after diagnosis.

CANADIAN JOURNAL OF CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology

Giuseppe M. C. Rosano et al.

Summary: Implementation of treatment in heart failure is hindered by poor tolerability and renal function issues, leading to difficulty in reaching target drug doses. A personalized approach to therapy based on patient profiles may be more effective than traditional forced titration of each drug class.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

Joao Pedro Ferreira et al.

Summary: In patients with heart failure and reduced ejection fraction, the effects of empagliflozin were similar in those using or not using MRAs. Empagliflozin treatment was associated with less discontinuation of MRAs.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed

Stephen J. Greene et al.

Summary: This viewpoint argues for increased use of quadruple therapy in patients with heart failure with reduced ejection fraction, emphasizing the importance of this approach in managing the condition effectively.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US

Lauren A. Eberly et al.

Summary: This study showed that Black and female patients as well as those with low socioeconomic status were less likely to receive SGLT2 inhibitor treatment among patients with type 2 diabetes in the US.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?

Abhinav Sharma et al.

Summary: Despite significant cardiovascular benefit of SGLT2 inhibitors and GLP-1 receptor agonists in T2DM patients, these therapies are underutilized due to therapeutic hesitancy. Clinicians may be reluctant to initiate cardiovascular protective therapies due to concerns about crossing interdisciplinary boundaries, potential harm from medication side effects, and uncertainty about optimal therapy choice. Multifaceted approaches, such as creating a culture of 'permission to prescribe' and enhancing trainees' experiences in cardiovascular disease prevention, are proposed to increase the implementation of evidence-based therapies and improve outcomes for individuals with T2DM.

CURRENT OPINION IN CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)

Gianluigi Savarese et al.

Summary: Despite the high risk of clinical events following heart failure hospitalization, new initiation of guideline-directed medical therapy (GDMT) was accompanied by consistent patterns of low up-titration and early discontinuation in three countries with different healthcare and economies.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial

Joao Pedro Ferreira et al.

Summary: The HEAAL trial found that in patients with HFrEF, men seemed to benefit more from high-dose losartan, while women appeared to have similar responses to low and high doses. Factors such as kidney function, age, and symptoms may also influence the response to high-dose losartan, suggesting that sex-based subgroup findings may be biased by other confounders.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial

Ankeet S. Bhatt et al.

Summary: The initiation of sacubitril/valsartan did not lead to increased discontinuation or dose reduction of other key guideline-directed medical therapies in HFrEF patients, and was associated with fewer discontinuations of MRA. Use of sacubitril/valsartan (compared with enalapril) may promote sustained MRA use in follow-up.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction

Justin T. Parizo et al.

Summary: In the study, dapagliflozin therapy was found to provide intermediate value compared to standard of care for patients with chronic heart failure with reduced ejection fraction. The cost-effectiveness of dapagliflozin therapy was sensitive to estimates of mortality reduction and duration of therapy effectiveness, with potential for cost reduction if the price of dapagliflozin decreased.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure

Abhinav Sharma et al.

ESC HEART FAILURE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF

Adam D. DeVore et al.

AMERICAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus Lessons Learned and Future Directions

Abhinav Sharma et al.

CIRCULATION (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

Milton Packer

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Kieran F. Docherty et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Estimating lifetime benefits of comprehensive disease -modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

Muthiah Vaduganathan et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Paul W. Armstrong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence

Phil McEwan et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Benefits of combination pharmacotherapy for HFrEF

Gregory B. Lim

NATURE REVIEWS CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski et al.

LANCET (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective

Subodh Verma et al.

ESC HEART FAILURE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction

Andrew D. M. Grant et al.

CJC OPEN (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial

Joao Pedro Ferreira et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction

Stephen J. Greene et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Petar M. Seferovic et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges

Catherine N. Marti et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

Add to Collection

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure

Eric J. Velazquez et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

John J. V. McMurray et al.

HEART (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure

Tarek Ajam et al.

AMERICAN JOURNAL OF CARDIOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

Maria G. Crespo-Leiro et al.

EUROPEAN JOURNAL OF HEART FAILURE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Medical Therapy for Heart Failure With Reduced Ejection Fraction

Stephen J. Greene et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes

Thomas A. Zelniker et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Public, Environmental & Occupational Health

Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study

Tiew-Hwa K. Teng et al.

LANCET GLOBAL HEALTH (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

Joao Pedro Ferreira et al.

EUROPEAN JOURNAL OF HEART FAILURE (2017)

Add to Collection

Review Cardiac & Cardiovascular Systems

Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives

Bertram Pitt et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure

Justin A. Ezekowitz et al.

CANADIAN JOURNAL OF CARDIOLOGY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy

Naoki Okumura et al.

CIRCULATION-HEART FAILURE (2016)

Add to Collection

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure

John J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy Analysis of the EMPHASIS- HF Study

Henry Krum et al.

CIRCULATION-HEART FAILURE (2013)

Add to Collection

Article Cardiac & Cardiovascular Systems

2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary

Clyde W. Yancy et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.

Faiez Zannad et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

Marvin A. Konstam et al.

LANCET (2009)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence - Results of the randomized cardiac insufficiency bisoprolol study (CIBIS) III

R Willenheimer et al.

CIRCULATION (2005)

Add to Collection

Article Medicine, General & Internal

Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure - Results from the ATLAS trial

BM Massie et al.

ARCHIVES OF INTERNAL MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.